Inactive Instrument

Neovasc Inc.

Equities

NVCN

CA64065J4037

Advanced Medical Equipment & Technology

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shockwave Medical Completes Acquisition of Neovasc MT
ShockWave Medical Closes Neovasc Acquisition; Shares Rise MT
Traders Cautious as Inflation Data, Fed Minutes Loom, Stifling US Equity Futures MT
Neovasc Inc.(NasdaqCM:NVCN) dropped from NASDAQ Composite Index CI
ShockWave Medical, Inc. completed the acquisition of Neovasc Inc. from Strul Medical Group LLC and others. CI
Neovasc Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Neovasc 2022 Loss Widens Ahead of Sale to Shockwave Medical MT
Neovasc Inc. Auditor Raises 'Going Concern' Doubt CI
Neovasc Shareholders Approve Proposed Takeover by Shockwave Medical MT
Neovasc Announced German Reimbursement Renewal MT
HC Wainwright Downgrades Neovasc to Neutral From Buy MT
Top Midday Gainers MT
ShockWave Medical to Acquire Neovasc in Initial $100 Million Deal; Neovasc Shares Jump MT
Shockwave Medical In Agreement to Acquire Neovasc MT
Transcript : Neovasc Inc., ShockWave Medical, Inc. - M&A Call
Neovasc Brief: Neovasc shareholders will also receive a potential deferred payment in form of a non-tradable contingent value right entitling holder to receive up to an additional US$12 per share in cash if certain regulatory milestones are achieved MT
Neovasc Brief: Shockwave Medical will acquire all outstanding Neovasc shares for an upfront cash payment of US$27.25 per share, corresponding to an enterprise value of approximately $100 million, inclusive of certain deal-related costs MT
Neovasc Brief: Shockwave Medical Announcing Agreement to Acquire Neovasc MT
ShockWave Medical, Inc. entered into a definitive agreement to acquire Neovasc Inc. from Strul Medical Group LLC and others for $75 million. CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday MT
MT Newswires Canada Overnight Stocks To Watch: Organigram; MEG Energy; Neovasc Inc MT
Neovasc Plans to Randomize 380 Patients in Reducer Trial MT
Neovasc Announces Progress on COSIRA-II Clinical Trial CI
Neovasc Reducer UK Case Study Published in European Heart Journal MT
Transcript : Neovasc Inc., Q3 2022 Earnings Call, Nov 10, 2022
Chart Neovasc Inc.
More charts
Neovasc Inc. is a Canada-based specialty medical device company. The Company develops, manufactures, and markets products for the cardiovascular marketplace. The Company is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The Company operates through one business segment: the development, manufacturing and marketing of medical devices. The Company's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The Company carries its business in Canada, the United States and Europe.
More about the company
  1. Stock
  2. Equities
  3. Stock Neovasc Inc. - Toronto S.E.
  4. News Neovasc Inc.
  5. Neovasc Provides Nasdaq Update, Also Says UK's National Institute for Health Provides Guidance for Neovasc Reducer